[Clinical assessment of dysarthria: presentation and validation of a method].
We adapted in French the Frenchay Dysarthria Assessment (FDA) developed by P. Enderby in 1983. This tool quantitatively evaluates the organs involved in speech and provides a measurement of intelligibility. Productions of normal subjects were analyzed. Reproductibility of data (correlation and interobserver concordance) was high in 18 dysarthric patients. A study performed in 100 dysarthric patients corresponding to 4 types of dysarthria (spastic, ataxic, hypokinetic and mixte) showed that dysarthria resulted from a global impairment of organs implied in speech, rather than one specific organ. The reduction in the intelligibility score was related to organ impairment.
Auzou
P
P
Service de Neurophysiologie, CHU, Rouen et Inserm U320, Caen.
Ozsancak
C
C
Jan
M
M
Léonardon
S
S
Ménard
J F
JF
Gaillard
M J
MJ
Eustache
F
F
Hannequin
D
D
D000368:Aged; D004401:Dysarthria / Q000145:classification / Q000503:physiopathology / Q000523:psychology*; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D008875:Middle Aged; D015588:Observer Variation; D012016:Reference Values; D015203:Reproducibility of Results; D013063:Speech Discrimination Tests; D013065:Speech Intelligibility
Evaluation clinique de la dysarthrie: présentation et validation d'une méthode.